AstraZeneca, Peregrine in clinical trial collaboration for drug to treat multiple solid tumors

24 August 2015
astrazeneca-large

Anglo-Swedish drug major AstraZeneca (LSE: AZN) on Monday said it has partnered with Peregrine Pharmaceuticals (Nasdaq: PPHM) for early stage trials for a drug to treat in multiple solid tumors.

The company in a statement said it will test the safety and efficacy of Peregrine’s drug candidate bavituximab with its own durvalumab in combination with chemotherapy as a potential treatment in various solid tumors.

Robert Iannone, head of immuno-oncology, at AstraZeneca, said: “We believe that combination therapy in immuno-oncology has the potential to be a novel and highly effective approach to treating cancer. Our partnership with Peregrine provides the opportunity to explore an exciting, novel combination that could deliver important clinical benefit to patients across a range of cancers.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical